Mutations in the aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1) cause the blinding disease Leber congenital amaurosis (LCA). The similarity of AIPL1 to AIP has led to suggestions that AIPL1 could function in a similar manner to AIP in facilitating protein translocation and as a component of chaperone complexes. AIPL1 interacts with the cell cycle regulator NEDD8 ultimate buster protein 1 (NUB1). As AIPL1 is predominantly cytoplasmic and NUB1 is predominantly nuclear, we tested the hypothesis that AIPL1 could modulate the nuclear translocation of NUB1. Co-transfection of AIPL1 with GFP-NUB1 resulted in a shift of GFP-NUB1 subcellular distribution toward the cytoplasm. Interestingly, AIPL1 was able to act in a chaperone-like fashion to efficiently suppress inclusion formation by NUB1 fragments. Co-transfection of AIPL1 with GFP-NUB1-N and GFP-NUB1-C resulted in an AIPL1-dependent suppression of GFP-NUB1-N perinuclear inclusions and GFP-NUB1-C intranuclear inclusions leading to the redistribution of these fragments in the cytoplasm. This chaperone-like function of AIPL1 was specific for NUB1, since AIPL1 was unable to suppress the inclusion formation by unrelated aggregation-prone proteins and AIP had no effect on NUB1 localization or inclusion formation. We examined the effect of a range of pathogenic and engineered mutations on the ability of AIPL1 to modulate NUB1 localization or inclusion formation. With the exception of W278X, which formed non-functional SDS-insoluble inclusions, all of the pathogenic mutations studied were soluble and could modulate NUB1 with varying efficiency compared with the wildtype protein. The effect of AIPL1 on NUB1 required the C-terminal region of AIPL1, as engineered C-terminal truncation mutations had no effect on NUB1. These data show that AIPL1 can modulate protein translocation and act in a chaperone-like manner and suggest that AIPL1 is an important modulator of NUB1 cellular function.
Mutations in the aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1) 1 cause up to 12% of Leber congenital amaurosis (LCA), an autosomal recessive disease characterized by severely impaired vision or blindness at birth (1) . AIPL1 is a photoreceptor-specific protein and the expression of AIPL1 closely follows the spatiotemporal differentiation of rod and cone photoreceptors in the developing human retina (2) . In the adult human retina, however, AIPL1 is expressed only in the rod photoreceptors, suggesting a potential switch in AIPL1 function between development and the adult (3). AIPL1 shares 49% identity and 69% similarity with human aryl hydrocarbon receptor-interacting protein (AIP), also named XAP2 or ARA9 (1, 4) . This similarity has led to the suggestion that AIPL1 may function in a similar manner (1, 4) . AIP exists in a cytosolic ternary complex with Hsp90 and the aryl hydrocarbon receptor (AhR) and is able to enhance the AhR transcriptional activity (5) (6) (7) . In the presence of ligand, the AhR undergoes nuclear translocation and transactivation. However, AIP mediates a distinct relocalization of ligand-free AhR to the cytoplasm and delays the nuclear translocation and accumulation of ligand-activated AhR, possibly by hindering the interaction with the nuclear import receptor protein importin-␤ (8 -11) . Furthermore, AIP stabilizes cytosolic AhR to ubiquitination and subsequent degradation mediated by the ubiquitin ligase protein, C-terminal Hsp70-interacting protein (CHIP) (9, (12) (13) (14) (15) .
AIPL1 interacts with the NEDD8 Ultimate Buster (NUB1) (16, 17, 18) ; however, the physiological significance of the interaction between AIPL1 and NUB1 is unknown. NUB1 was identified through its interaction with the ubiquitin-like protein NEDD8 and targets NEDD8 and NEDD8 conjugates for proteasomal degradation (19, 20) . Recently, a splicing variant of NUB1 possessing a 14-amino acid insertion in the C terminus (NUB1L) was identified (21) . NUB1L was shown to interact with NEDD8 as well as an additional ubiquitin-like protein FAT10, and to accelerate the proteasomal degradation of these ubiquitin-like proteins (22) . In addition, both NUB1 and NUB1L interact with a ubiquitin precursor UbC1 and mediate the hydrolysis of UbC1 by an unidentified ubiquitin C-terminal hydrolase (UCH) (17) . NEDD8 is conjugated specifically to members of the cullin (Cul) family in a manner analogous to ubiquitination and sentrinization (23) . The cullins are components of an SCF ubiquitin E3 ligase composed of Skp1, cullin, F-box protein, and ROC1 (24) . The Cul-1 SCF complex catalyzes the ubiquitination of IB␣, ␤-catenin, cyclin D proteins, p27 (KIP1), and p21 (CIP1/WAF1), and NEDD8 conjugation is necessary for the ubiquitin ligase activity of the Cul-1 SCF complex (25) (26) (27) (28) (29) . The Cul-2 and Cul-3 SCF complexes target hypoxia-inducible factor-1␣ (HIF1␣) and cyclin E respectively for ubiquitination and proteasomal degradation (30, 31) . Therefore, NEDD8 cullin conjugation has been implicated in many important biological events, including cell signaling and cell cycle regulation. It has been suggested that the interaction of AIPL1 with NUB1 implicates AIPL1 in biological functions related to NUB1 such as cell growth and cell cycle regulation, but the cellular role of AIPL1 with respect to NUB1 still remains to be fully determined.
We recently examined the expression and localization of AIPL1 and NUB1 in the adult and developing human retina (2) . AIPL1 was predominantly cytoplasmic, whereas NUB1 was predominantly nuclear because of a functional nuclear localization signal (NLS) near the C terminus (2, 3, 19, 21) . Therefore, we tested the hypothesis that AIPL1 could modulate NUB1 nuclear translocation similar to the role of AIP with the AhR. The data show that AIPL1 is able to regulate the translocation of NUB1, thereby potentially modulating downstream effects of NUB1 on cell signaling and cell growth.
EXPERIMENTAL PROCEDURES
Plasmids and Mutagenesis-Full-length AIPL1 was amplified from human retinal cDNA using AIPL1-specific primers. The PCR product was cloned into pBK-CMV (Stratagene, La Jolla, CA) to produce pBK-CMV-AIPL1 encoding untagged AIPL1 and into pCMV-Tag3C (Stratagene) in-frame with an N-terminal c-myc tag to produce pCMV-Tag3C-AIPL1. The pCMV-Tag3C-AIPL1 plasmid was used as the template for generation of point and deletion mutants using site-specific primers and the QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. Full-length NUB1 was amplified from a human retinal cDNA library. The NUB1 PCR product was cloned into pEGFP-C1 (Clontech, Palo Alto, CA) in-frame with a GFP tag to produce pEGFP-C1-NUB1. The QuikChange site-directed mutagenesis kit and site-specific primers were used to produce pEGFP-C1-NUB1-N (residues 1-306). pEGFP-C2-NUB1-C (residues 347-601) was produced by digesting pEGFP-C1-NUB1 with BamHI and ligating the C-terminal NUB1 fragment into pEGFP-C2 in-frame with the GFP tag. All plasmids were sequenced using the Big Dye Terminator (PerkinElmer Life Sciences) ready reaction sequencing kit in order to confirm the absence of unintentional changes and the presence of desired mutations. The plasmid mycXAP2 1-330/cDNA3 was a gift from M. Whitelaw, University of Adelaide, Australia. The plasmid c-myc-Ub was a gift from R.R. Kopito, Stanford University. GFP-Q25 and GFP-Q103 were kind gifts from D. C. Rubinsztein, Cambridge Institute for Medical Research. pEGFP-WT and pEGFP-P23H have been described previously (32) .
Cell Culture, Transfection, and Counting-SK-N-SH neuroblastoma cells were cultured in Dulbecco's modified Eagle's medium/F12 (Invitrogen Life Technologies). 24 h after seeding glass eight well chamber slides with 2 ϫ 10 4 cells per well, the cells were transiently transfected at 50 -60% confluency using LipofectAMINE Plus Reagent (Invitrogen Life Technologies) according to the manufacturer's instructions. For concentration-dependent studies, increasing amounts of the plasmid of interest were co-transfected with 50 ng of pEGFP-C1-NUB1, pEGFP-C1-NUB1-N, or pEGFP-C2-NUB1-C at a ratio (w/w) of 0:1, 0.5:1, 1:1, and 2:1, and with pCMV-Tag3C stuffer plasmid to maintain an equal amount (150 ng) of total DNA in each transfection. Four fields of ϳ100-transfected cells each were counted using a Leica DM RBE fluorescent microscope in at least three separate experiments. The distribution of GFP-NUB1 in transfected cells was classified as more nuclear (N Ͼ C), more cytoplasmic (C Ͼ N) or equally distributed in the cytoplasm and the nucleus (N ϭ C). In addition, fluorescence images were captured using a PerkinElmer Ultrapix standard peltier cooled CCD camera and LSR Ultra Plus version 4.1 Spatial Imaging Module. ImageJ (rsb.info.nih.gov/ij/) was used to assess the OD of GFP-NUB1 fluorescence in the nucleus and whole cell of ϳ100 transfected cells. For each cell, the percentage of fluorescence in the nucleus was calculated using the following equation: (mean OD nucleus ϫ Area nucleus /mean OD total ϫ Area total ) ϫ 100. Mean and standard deviation were calculated for each data set.
Immunocytochemistry-24 h following cell transfection as described above, cells were processed for immunocytochemistry as described previously (3, 33) . Primary antibodies used in immunofluorescent labeling included rabbit polyclonal antiserum Ab-hAIPL1 (2, 3), mouse monoclonal anti-heat shock protein 70 antibody that detects both Hsc70 and Hsp70 (clone BRM-22 ascites fluid) (Sigma) and mouse monoclonal anti-myc antibody (clone 9E10 ascites fluid). Ab-hAIPL1, BRM22, and 9E10 were used at the respective titers of 1:250, 1:50, and 1:200. Cy3-conjugated donkey-anti-rabbit (Molecular Probes, Eugene, OR) or Cy3-conjugated donkey anti-mouse (Molecular Probes) secondary antibodies were used at a titer of 1:100. The cells were mounted in fluorescent mounting medium and visualized with a Zeiss LSM510 laser scanning confocal microscope.
Cell Extracts and Western Blotting-24 h after transfection, the SK-N-SH cells were washed three times with Hank's balanced salts without calcium and magnesium (HBSS) (Invitrogen Life Technologies) and trypsinized with trypsin-EDTA solution (1ϫ) (Sigma). The cells were washed twice in 100 volumes of ice-cold PBS and collected by centrifugation for 5 min at 600 ϫ g and 4°C. The cells were lysed on ice for 3 min with gentle agitation in 10 volumes of phosphate-buffered saline containing 0.5% Nonidet P-40 and 10% mammalian protease inhibitor mixture (Sigma). The cells were pelleted by centrifugation for 5 min at 1000 ϫ g and 4°C, and the soluble fraction was removed. The protein concentration in the soluble fraction was measured with the Bio-Rad reagent using bovine serum albumin as a standard. Proteins were resolved by denaturing SDS-PAGE and transferred to nitrocellulose membrane. Western analysis was performed as described previously (2, 3). The rabbit polyclonal antiserum Ab-hNUB1 has been described previously (2, 3) . Ab-hAIPL, Ab-hNUB1, Living colors A.v. Peptide antibody (BD Biosciences, Oxford, UK) and 9E10 were used at the respective titers of 1:2000, 1:20,000, 1:250, and 1:1000. Horseradish peroxidase-coupled goat anti-rabbit or goat anti-mouse secondary antibodies (Pierce) were used at a titer of 1:30,000. Membranes were developed using chemiluminescence (Amersham Biosciences).
Filter Trap Assay-Cell extracts were prepared as described above, but were lysed in 10 volumes of SDS-lysis buffer (10 mM Tris.HCl, pH 8.0; 150 mM NaCl; 2% SDS; 10% mammalian protease inhibitor mixture (Sigma)) and sonicated for 10 s. The samples were boiled for 2 min and immediately applied to a 0.2-m cellulose acetate membrane equilibrated with two washes of SDS wash buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% SDS) on a dot blot apparatus (Bio-Rad) using a vacuum manifold. After a 20-min incubation at room temperature, the membrane was washed three times with SDS wash buffer. The membrane was removed and Western blotted as described above.
RESULTS

AIPL1 Is Able to Modulate the Subcellular Distribution of GFP-NUB1-
The subcellular distribution of GFP-NUB1 in SK-N-SH cells with increasing concentrations of myc-AIPL1 was examined by immunofluorescent confocal microscopy. In the absence of myc-AIPL1, GFP-NUB1 was predominantly nuclear (Fig. 1A, CON) , as has been shown for the endogenous NUB1 protein and HA-tagged NUB1 (2, 19, 21) . However, increasing amounts of the myc-AIPL1 plasmid led to a shift in the subcellular distribution of GFP-NUB1 toward the cytoplasm. At the highest concentration of myc-AIPL1 (pEGFP-C1-NUB1: pCMV-Tag3C-AIPL1 ϭ 1:2), the GFP-NUB1 signal was more intense in the cytoplasm than in the nucleus of some transfected cells (Fig. 1A, ϩAIPL1) . Double blind counting of cells demonstrated that in the presence of myc-AIPL1, GFP-NUB1 was predominantly cytoplasmic (C Ͼ N) in ϳ14% of transfected cells, whereas in the absence of myc-AIPL1 no transfected cells had more GFP-NUB1 in their cytoplasm (Fig. 1B ). There was a concomitant decrease in the percentage of transfected cells with a predominantly nuclear (NϾC) GFP-NUB1 distribution from ϳ75 to ϳ59% (Fig. 1B) . In order to confirm these observations, image analyses was used to measure the percentage of GFP-NUB1 fluorescence in the nucleus in the absence (Fig. 1C,  CON) and presence of AIPL1 (Fig. 1C, ϩAIPL1 ). GFP-NUB1 had a mean OD percentage of 61% in the nucleus, in the presence of AIPL1 this dropped to 39%. Hence, myc-AIPL1 was able to modulate the subcellular distribution of GFP-NUB1. Similar results were obtained with untagged AIPL1 (data not shown).
To test the specificity of the AIPL1 effect, the effect of the AIPL1 homologue XAP2 (AIP) on the subcellular distribution of GFP-NUB1 was examined. pEGFP-C1-NUB1 was co-transfected with increasing amounts of mycXAP2 1-330/cDNA3 and analyzed by immunofluorescent confocal microscopy and double blind cell counting. GFP-NUB1 was predominantly nuclear, both in the absence and the presence of XAP2 (Fig. 1A, CON,  ϩXAP2) . Double blind cell counting demonstrated that there was no change in the subcellular distribution of GFP-NUB1 in the presence of XAP2 (Fig. 1B) . Even at the highest concentrations of XAP2 no cells were counted in which the distribution of GFP-NUB1 was predominantly cytoplasmic (CϾN) (Fig. 1B) . Therefore, while AIPL1 was able to modulate the subcellular distribution of GFP-NUB1, the closely related AIPL1 homologue XAP2 had no effect on the subcellular distribution of GFP-NUB1.
AIPL1 Is Able to Suppress the Formation of GFP-NUB1-N and GFP-NUB1-C Inclusions-
There are a number of conserved motifs clustering toward either the N-or C-terminal domain of full-length NUB1 including two coiled-coil (cc) domains (residues 36 -67 and 155-203) and a ubiquitin-like (UBL) domain (residues 85-147) near the N terminus, and two ubiquitin-associated (UBA) domains (residues 376 -413 and 477-514), an NLS (residues 414 -431), and a PEST sequence (residues 514 -568) toward the C terminus ( Fig. 2A) . In order to determine whether the effect of AIPL1 on the subcellular distribution of NUB1 was modulated through either the N-or C-terminal domain of NUB1, GFP-NUB1-N (residues 1-306 of NUB1 including the N-terminal motifs), and GFP-NUB1-C (residues 347-601 of NUB1 including the C-terminal motifs) were constructed ( Fig. 2A) .
pEGFP-C1-NUB1-N and pEGFP-C2-NUB1-C were transiently transfected into SK-N-SH cells in the presence of increasing concentrations of pCMV-Tag3C-AIPL1 and analyzed by immunofluorescent confocal microscopy and cell counting. In the absence of myc-AIPL1, GFP-NUB1-N, which lacks the C-terminal NUB1 motifs including the NLS, was detected in multiple small inclusions (Fig. 2B, ϪAIPL1 ). These inclusions were cytoplasmic but decorated the nucleus in a perinuclear fashion as assessed by confocal optical sectioning with a nuclear counterstain (data not shown). However in the presence of myc-AIPL, GFP-NUB1-N was detected as a diffuse staining pattern in the cytoplasm of transfected cells (Fig. 2B, ϩAIPL1) . Upon cell counting, suppression of GFP-NUB1-N inclusion formation with increasing concentrations of myc-AIPL1 was revealed ( Fig. 2C ). The incidence of GFP-NUB1-N inclusions dropped by more than half when the amount of pCMV-Tag3C-AIPL1 used was only half that of pEGFP-C1-NUB1-N. At the highest concentration of myc-AIPL1, only ϳ0.5% of transfected cells contained GFP-NUB1-N inclusions (Fig. 2C) . Hence, myc-AIPL1 was able to suppress the formation of GFP-NUB1-N inclusions and redistributed GFP-NUB1-N in the cytoplasm.
In the absence of myc-AIPL1, GFP-NUB1-C was detected in large, intranuclear inclusions (Fig. 2D, ϪAIPL1 ). In the presence of myc-AIPL1, however, GFP-NUB1-C was diffusely distributed throughout the cytoplasm and to a lesser extent in the nucleus of transfected cells (Fig. 2D, ϩAIPL1) . Cell counting demonstrated a myc-AIPL1-dependent suppression of GFP-NUB1-C intranuclear inclusions (Fig. 2E) . The number of transfectants with inclusions dropped from ϳ26% in the absence of myc-AIPL1 to ϳ6% at the highest concentration of myc-AIPL1. Hence, myc-AIPL1 was able to suppress the formation of GFP-NUB1-C inclusions, and, furthermore, redistribute GFP-NUB1-C in the cytoplasm. The AIPL1-mediated suppression of GFP-NUB1-C inclusion formation was less efficient than that of GFP-NUB1-N. Similar results were obtained with untagged AIPL1 (data not shown). 
Characterization of GFP-NUB1-N and GFP-NUB1-C Inclusions-
To assess the nature of the GFP-NUB1-N and GFP-NUB1-C inclusions, a peptide antibody directed against GFP was used to screen total cell extracts assessed using the filter trap assay and soluble fractions analyzed by Western blotting (Fig. 3A) . GFP-Q25 and GFP-Q103 were used as controls in the filter trap assay. GFP-Q103 encodes exon 1 of the human huntingtin (HD) gene with 103 polyglutamine (poly(Q)) repeats and is aggregation-prone while GFP-Q25, encoding only 25 poly(Q) repeats remains soluble (34) . In the filter trap assay, only GFP-Q103 formed SDS-insoluble inclusions that could be trapped on the 0.2-m cellulose acetate membrane (Fig. 3A) . GFP-Q25, GFP-NUB1, GFP-NUB1-N, and GFP-NUB1-C were SDS-soluble and were not trapped on the 0.2-m cellulose acetate membrane (Fig. 3A) . Western analysis detected a band of ϳ97 kDa, 63 kDa, and 56 kDa corresponding to the predicted molecular mass for GFP-NUB1, GFP-NUB1-N, and GFP-NUB1-C, respectively (Fig. 3A) . While GFP-NUB1 and GFP-NUB1-C were detected at roughly equivalent levels in cell extracts, much less GFP-NUB1-N was expressed. The GFP-NUB1-N and GFP-NUB1-C inclusions were SDS-soluble, as they were resolved by reducing SDS-PAGE and were not trapped on the 0.2-m cellulose acetate membrane using the filter trap assay.
The co-localization of GFP-NUB1, GFP-NUB1-N, and GFP-NUB1-C with AIPL1, Hsp70, and ubiquitin in SK-N-SH cells was examined using double labeling immunofluorescent confocal microscopy (Fig. 3B) . At the highest concentration of myc-AIPL1, GFP-NUB1, and myc-AIPL1 co-localized with the greatest intensity in the cytoplasm of SK-N-SH transfected cells. At the lowest concentration of myc-AIPL1, the GFP-NUB1-N inclusions were dispersed and GFP-NUB1-N co-localized with myc-AIPL1 in the cytoplasm. Occasionally, a single small remaining GFP-NUB1-N extranuclear inclusion was detected and myc-AIPL1 co-localized with this single remaining inclusion (white arrowhead). At the lowest concentration of myc-AIPL1, GFP-NUB1-C co-localized with myc-AIPL1 in the cytoplasm and residual GFP-NUB1-C inclusions could be detected in the nucleus of transfected cells. myc-AIPL1 co-localized with GFP-NUB1-C in the cytoplasm as well as in the residual intranuclear inclusion. The subcellular distribution of endogenous Hsc70/Hsp70 and myc-ubiquitin was examined in SK-N-SH cells transfected with GFP-NUB1, GFP-NUB1-N, and GFP-NUB1-C (Fig. 3B) . Hsc70/Hsp70 and myc-ubiquitin co-localized with the GFP-NUB1-N extranuclear inclusions and GFP-NUB1-C intranuclear inclusions. Hence, both Hsc70/ Hsp70 and ubiquitin were recruited to the GFP-NUB1-N and GFP-NUB1-C inclusions.
Specificity of AIPL1-mediated Protein Inclusion Suppression-To determine whether the AIPL1-mediated suppression of GFP-NUB1-N and GFP-NUB1-C inclusion formation was related to a general chaperone function the effect of myc-AIPL1 on the aggregation prone proteins P23H-GFP and GFP-Q103 was assessed. WT-GFP and P23H-GFP are GFP-tagged wildtype opsin and an aggresome-forming mutant opsin, respectively (32) . Increasing concentrations of myc-AIPL1 had no effect on either WT-GFP or GFP-Q25 (data not shown). In the absence of myc-AIPL1, ϳ40% of cells transfected with P23H-GFP contained inclusions, and this percentage was not significantly altered by the addition of increasing concentrations of myc-AIPL1 (Fig. 4A) . In the absence of myc-AIPL1, GFP-Q103 inclusions were present in ϳ43% of transfected cells (Fig. 4B) . No significant decrease in the percentage of GFP-Q103 inclusions was observed with increasing myc-AIPL1 concentrations, with the exception of cells co-transfected with twice as much myc-AIPL1 as GFP-Q103 (Fig. 4B) . In this case a slight reduction in the percentage of cells with inclusions was observed (ϳ35%), although the change in the percentage of cells with GFP-Q103 inclusions did not show a myc-AIPL1-dependent trend. Therefore, the effect of AIPL1 on the suppression of inclusion formation appears to be specific for the NUB1 constructs, GFP-NUB1-N and GFP-NUB1-C.
Characterization of AIPL1 Mutants-At the primary structural level, AIPL1 contains three central tetratricopeptide repeat (TPR) motifs (TPR1, TPR2, and TPR3) and a C-terminal primate-specific polyproline-rich (PP) region of 56 amino acids (Fig. 5A) (1) . In order to further characterize the effect of AIPL1 on GFP-NUB1, GFP-NUB1-N, and GFP-NUB1-C, a number of disease-associated mutations were generated including A197P, C239R, G262S, W278X, R302L, and P351⌬12 (www.retinainternational.com/sci-news/aipl1mut.htm) (Fig. 5A) . In addition, three mutations as yet undescribed in patients were designed K265A, E317X, and Q329X (Fig. 5A) . The lysine residue at position 265 in TPR3 of AIPL1 is conserved in all species, as well as in TPR3 of human and mouse AIP, human FKBP51 and FKBP52, and the TPR co-chaperone protein phosphatase 5 (PP5). This residue is essential in formation of the TPR carboxylate clamp that mediates the interaction of the TPR cochaperones with the MEEVD TPR acceptor motif of Hsp90, and mutation of this residue has been shown to abrogate the asso- ciation of AIP, FKBP51, FKBP52, and PP5 with Hsp90 (35, 36) . The replacement of the glutamic acid residue at position 317 in AIPL1 with a stop codon removed the C terminus of AIPL1 upstream of the primate-specific PP region. In FKBP51 and FKBP52, the replacement of the equivalent residue with a stop codon leaves the ␣-helical packing of the core TPR region intact but removes the remainder of the seventh extended ␣-helix (37). This residue has been shown to be important in determining the requirement of the region C-terminal to the TPR domain for the interaction of FKBP51 and FKBP52 with Hsp90 (37). Finally, the replacement of glutamine with a stop codon at position 329 in AIPL1 removed the primate-specific PP region. All the pCMV-Tag3C-AIPL1 mutants were transiently transfected into SK-N-SH cells, soluble extracts were prepared and analyzed by reducing SDS-PAGE and Western blotting (Fig.  5B ). Western blotting with Ab-hAIPL1 (Fig. 5B, ␣AIPL1) or 9E10 (Fig. 5B, ␣myc) detected a band of ϳ46 kDa for all of the mutants corresponding to their predicted molecular sizes with the exception of W278X, E317X, and Q329X, all of which are C-terminal truncation mutants, which lack the epitope for AbhAIPL1 (Fig. 5A ). 9E10 detected a band of ϳ39 kDa and ϳ41 kDa corresponding to the predicted molecular sizes for E317X and Q329X, respectively. W278X could not be resolved by reducing SDS-PAGE, but could be trapped on a 0.2-M cellulose acetate membrane using the filter trap assay (Fig. 5B) . All of the myc-AIPL1 mutants were assessed by immunocytochemistry (Fig. 5, C and D) . As previously shown for AIPL1 (3), myc-AIPL1 was detected in the cytoplasm and nucleus of transfected SK-N-SH cells, but the immunostain was more intense in the cytoplasm than in the nucleus (Fig. 5C, AIPL1) . The subcellular distribution of all the myc-AIPL1 mutants was similar to that of myc-AIPL1, with the exception of W278X, which formed multiple small inclusions in the cytoplasm of transfected cells (Fig. 5D, AIPL1(W278X) ). Hence, while all the mutants were SDS-soluble and were similar to myc-AIPL1 in their subcellular distribution, myc-AIPL1(W278X) formed SDS-insoluble cytoplasmic inclusions.
The Ability of AIPL1 to Modulate the Subcellular Distribution of GFP-NUB1 and Suppress the Formation of GFP-NUB1-N and GFP-NUB1-C Inclusions Requires a C-terminal
Region of AIPL1-To assess the effect of the myc-AIPL1 mutants on the subcellular distribution of GFP-NUB1, GFP-NUB1 was co-transfected with myc-AIPL1 or the myc-AIPL1 mutants at a ratio of 1:2 and the percentage of GFP-NUB1 transfectants, which were predominantly cytoplasmic (CϾN) were counted (Fig. 6A) . The ability of AIPL1 to modulate the nuclear localization of GFP-NUB1 was the most efficient at this ratio of co-transfected DNA. To assess the ability of the AIPL1 mutants to suppress the formation of GFP-NUB1-N inclusions, GFP-NUB1-N was co-transfected with myc-AIPL1 or the myc-AIPL1 mutants at a ratio of 1:0.5 and the percentage of GFP-NUB1-N extranuclear inclusions were counted (Fig. 6B) . GFP-NUB1-C was co-transfected with myc-AIPL1 or the myc-AIPL1 mutants at a ratio of 1:1 and the percentage of GFP-NUB1-C intranuclear inclusions were counted (Fig. 6C) . AIPL1 was moderately efficient at suppressing inclusion formation at these ratios of co-transfected DNA ensuring that a sufficient number of inclusions would remain for counting (Fig. 2) . The effect of myc-AIPL1, the myc-AIPL1 mutants and XAP2 on the modulation of GFP-NUB1 nuclear localization and the suppression of GFP-NUB1-N and GFP-NUB1-C inclusions was summarized (Table I ). A197P and C239R were as effective as myc-AIPL1 in modulating the subcellular distribution of GFP-NUB1 and suppressing GFP-NUB1-N and GFP-NUB1-C inclusion formation (Fig. 6, A197P, C239R) . K265A was equally efficient in modulating the subcellular distribution of GFP-NUB1, but slightly less efficient at mediating the suppression of GFP-NUB1-N and GFP-NUB1-C inclusions (Fig. 6, K265A) . P351⌬12, which resides in the C-terminal PP region of AIPL1, was equally efficient as myc-AIPL1 in mediating GFP-NUB1 redistribution and GFP-NUB1-C inclusion suppression, and only slightly less efficient than myc-AIPL1 in suppressing the formation of GFP-NUB1-N inclusions (Fig. 6, P351⌬12) . Both W278X and E317X were completely defective with respect to all three activities, while R302L had residual activity (Fig. 6,  W278X, E317X, R302L ). The C-terminal truncation mutant Q329X was also defective with respect to modulating the subcellular distribution of GFP-NUB1 and suppressing GFP-NUB1-N inclusion formation, but retained residual activity with respect to suppressing GFP-NUB1-C inclusion formation (Fig. 6, Q329X) . The mutant G262S was unusual in that its behavior was not consistent with respect to all three activities. G262S was hyperactive in modulating the subcellular distribution of GFP-NUB1, slightly less efficient than wild type in mediating GFP-NUB1-N suppression and equally efficient as wild type in mediating suppression of GFP-NUB1-C inclusions (Fig. 6, G262S) . Collectively, the data indicated that the Cterminal domain of AIPL1 was important for AIPL1 to modulate GFP-NUB1 subcellular localization and suppress the formation of GFP-NUB1-N and GFP-NUB1-C inclusions. XAP2 was unable to modulate the nuclear localization of GFP-NUB1 or suppress the formation of GFP-NUB1-N and GFP-NUB1-C inclusions when compared with AIPL1 (Fig. 6, XAP2) . DISCUSSION We have previously demonstrated that NUB1 is predominantly nuclear in cell lines and in human tissues, while the photoreceptor-specific AIPL1 is predominantly cytoplasmic (2,  3) . Here, we demonstrate that AIPL1 was able to modulate the 
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nuclear localization of NUB1. The data suggest that AIPL1 is able to retain NUB1 in the cytoplasm or inhibit the nuclear translocation of NUB1, since NUB1 co-localized with AIPL1 in the cytoplasm. Similarly, it has been shown that the AIPL1 homologue AIP is able to mediate a shift in the subcellular distribution of the AhR toward the cytoplasm (8 -10) . It is possible that AIPL1 may employ similar mechanisms to AIP to regulate the subcellular distribution of NUB1. For example, it has been shown that AIP retains the AhR in the cytoplasm by inhibiting the nucleocytoplasmic shuttling of the AhR and altering the conformation of the AhR NLS, thereby inhibiting the interaction of the AhR with importin-␤ (10, 11). In addition, it has been shown that AIP can interact with and maintain mitochondrial preproteins in an import-competent conformation and facilitate preprotein import into the mitochondria (38) . Similarly, it is possible that AIPL1 may modulate the conformation and nuclear import competency of NUB1. It is important to note, however, that the effect of AIPL1 on NUB1 was specific to AIPL1, since AIP had no effect on the subcellular modulation of NUB1. Therefore, AIPL1 and AIP may perform similar functions that are mutually exclusive with respect to NUB1 and the AhR, since AIPL1 is unable to interact with the AhR and AIP is unable to interact with NUB1 (39) .
In addition to its role in protein translocation, AIP has been shown to have a chaperone activity (38) . Interestingly, N-and C-terminal fragments of NUB1 formed intracellular inclusions when expressed coupled to GFP or myc-tagged (data not shown). Hsp70 and ubiquitin were recruited to these inclusions, suggesting that they may be targeted for proteasomal degradation. The recruitment of Hsp70 and ubiquitin is a common feature of other intracellular protein inclusions, including those formed by rhodopsin P23H-GFP and huntingtin exon 1 GFP-Q103 (32, 34) . Unlike these inclusions, however, the NUB1 fragment inclusions were SDS-soluble. AIPL1 was able to suppress the formation of both GFP-NUB1-N and GFP-NUB1-C inclusions, and redistribute these fragments in the cytoplasm. Interestingly, the AIPL1-mediated shift of GFP-NUB1-C from the nucleus to the cytoplasm was more pronounced than the effect of AIPL1 on full-length GFP-NUB1. This may be due to the elements within the N terminus of the full-length protein, which mediate the retention of the protein in the nucleus. The ability of AIPL1 to suppress NUB1 inclusion formation does not appear to be a general chaperone function, as AIPL1 was unable to suppress the formation of inclusions formed by GFP-Q103 or P23H-GFP. The mechanisms of NUB1 fragment inclusion formation remain to be determined and may be different for the N-and C-terminal fragments as their appearance and subcellular distribution are different. Nevertheless, inclusion formation is likely to reflect either an inherent instability of the structure of these domains in isolation or result from protein-protein associations, which require the full-length protein for proper regulation. Therefore, AIPL1 may function to stabilize the conformation of NUB1 or regulate NUB1 complex formation. It is interesting to note that 
TABLE I Modulation of GFP-NUB1 constructs by AIPL1 mutants
The efficiency is rated as: Ϫ, no activity; ϩ/Ϫ, residual activity; ϩ, less efficient than AIPL1; ϩϩ, comparatively efficient to AIPL1; ϩϩϩ, more efficient than AIPL1.
the AIPL1 binding site in NUB1 has been mapped to the extreme C terminus of NUB1 upstream of the PEST sequence (residues 569 -601) by yeast two-hybrid analysis (18) . However, we clearly show an effect of AIPL1 with both the Nterminal region (residues 1-306), as well as the C-terminal region (residues 347-601) of NUB1. Collectively, the data suggest a complex interaction between AIPL1 and NUB1, which may involve additional components in a multiprotein heterocomplex.
We engineered a number of mutations in AIPL1 (K265A, E317X, and Q329X) to test the TPR and C-terminal domain requirements for NUB1. All of these AIPL1 mutants were SDS-soluble and their subcellular distribution was not significantly altered when compared with wild-type AIPL1. K265A was able to modulate the nuclear localization of GFP-NUB1 as efficiently as AIPL1 and was only slightly less efficient than AIPL1 in mediating a suppression of GFP-NUB1-N and GFP-NUB1-C inclusion formation. The equivalent mutation in AIP, FKBP51, FKBP52, and PP5 abolishes the interaction of these TPR co-chaperones with the molecular chaperone Hsp90 (35, 36) . Since the activity of K265A was largely unaffected, the data suggest that this TPR residue is not essential for the ability of AIPL1 to modulate NUB1 nuclear localization and suppress NUB1 fragment inclusion formation. The C-terminal truncation mutant E317X removed the C-terminal region of AIPL1 11 residues upstream of the termination signal for all non-primate AIPL1 orthologues including the predicted extended ␣-helical domain of TPR3. E317X was defective with respect to all activities, suggesting that C-terminal sequences in AIPL1 are necessary for the modulation of NUB1 nuclear localization and inclusion suppression. The C-terminal truncation mutant Q329X removed the C-terminal primate-specific polyproline-rich region of AIPL1. This mutant was defective with respect to GFP-NUB1 subcellular modulation and GFP-NUB1-N inclusion suppression but was residually active in suppressing GFP-NUB1-C inclusions. However, it is interesting to note that the NUB1 binding site in AIPL1 has been mapped between residues 181 and 330 by yeast two-hybrid analysis and in vitro protein binding assays, suggesting that the primate-specific PP region is dispensable for NUB1 interaction (18) . Our data suggest that the PP region is necessary for AIPL1 to modulate NUB1 subcellular distribution and suppression of NUB1 fragment inclusion formation, although individual residues within this region may be dispensable for the activity of AIPL1 with respect to NUB1 and NUB1 fragments (e.g. P351⌬12 see below). The requirement for part of the PP region of AIPL1 for these NUB1 related functions suggests a potential specialization in primate AIPL1 specifically related to the modulation of NUB1, but this will require further investigation to test whether non-primate AIPL1 orthologues can perform similar functions for non-primate NUB1 proteins and to determine the role of the PP region in the structure of primate AIPL1.
The disease-associated mutations engineered in AIPL1 included A197P, C239R, G262S, W278X, R302L, and P351⌬12. With the exception of W278X, all of these AIPL1 mutants were SDS-soluble and their subcellular distribution was not significantly altered when compared with wild-type AIPL1. W278X was defective with respect to all activities when compared with wild-type AIPL1. The tryptophan residue at position 278 is conserved in all species. The mutation W278X removes the C-terminal 107 amino acids of AIPL1 including most of TPR3 and the primate-specific region. W278X formed SDS-insoluble cytoplasmic inclusions, suggesting that the mutant protein undergoes misfolding and aggregation, and is therefore non-functional.
The mutants A197P and C239R were as efficient as wild type AIPL1 in modulating the nuclear localization of GFP-NUB1 and suppressing the formation of GFP-NUB1-N and GFP-NUB1-C inclusions. The alanine residue at position 197 and cysteine residue at position 239 are conserved in all species of AIPL1. Yeast two-hybrid analysis has demonstrated that the mutants A197P and C239R are able to interact with NUB1 (16) . However, reciprocal yeast two-hybrid analysis and in vitro protein binding assays have failed to demonstrate the interaction between these mutants and NUB1 (18) . Our data are supportive of an interaction of the A197P and C239R mutants with NUB1. The mutant G262S was hyperactive with respect to the modulation of GFP-NUB1 nuclear localization, slightly less efficient than wild type AIPL1 with respect to GFP-NUB1-N inclusion suppression and equally efficient with respect to GFP-NUB1-C inclusion suppression. This glycine is conserved in all species of AIPL1 thus far sequenced, and it is possible that the G262S mutation may favor an AIPL1 conformation that confers hyperactivity with respect to NUB1 nuclear localization.
The mutant R302L had a slightly reduced activity with respect to the modulation of GFP-NUB1 subcellular distribution and the suppression of GFP-NUB1-N and GFP-NUB1-C inclusions. The arginine residue at position 302 in AIPL1 is conserved in all primates. However this residue is glutamine in bovine and leucine in rodents and it has thus been suggested that R302L may not be a disease-causing variant of AIPL1 (1). Our data suggest that although R302L can interact with NUB1, this amino acid substitution impacts negatively on the ability of AIPL1 to modulate NUB1 nuclear localization and suppress the formation of inclusions by NUB1 fragments, perhaps by affecting the conformation of the proposed NUB1 binding site within which the mutation resides. Finally, the mutant P351⌬12 was able to modulate GFP-NUB1 nuclear localization and suppress the formation of GFP-NUB1-N and GFP-NUB1-C inclusions. Interestingly, all the disease-associated mutations described here have been shown to cause recessive LCA, with the exception of P351⌬12, which has been associated with the clinical diagnosis of autosomal dominant cone-rod dystrophy and juvenile retinitis pigmentosa (RP) (40) .
The disease-associated mutations A197P, C239R, G262S, and P351⌬12 were similar to wild-type AIPL1 with respect to the effect of AIPL1 on NUB1, suggesting that the basis for disease in these patients may involve the interaction of AIPL1 with an alternative binding partner. For example, it has been shown that AIPL1 is able to interact with and enhance the processing of farnesylated proteins (39) . It has been demonstrated that the AIPL1 mutants A197P and C239R, which were functional with respect to their effect on NUB1, were defective with respect to the interaction with and processing of farnesylated proteins (39) . Until we fully understand the consequences of the AIPL1:NUB1 interaction, however, it will not be possible to determine whether these mutations are competent for all aspects of AIPL1-mediated regulation of NUB1. Nevertheless, our data suggest that in some patients (e.g. R302L and W278X) AIPL1 is unable to effectively modulate the subcellular distribution and nuclear translocation of NUB1, potentially affecting events downstream of NUB1 including the regulation of cell signaling and cell growth and highlighting a possible mechanism of disease. This is the first study to demonstrate that the similarity between AIP and AIPL1 does correlate with a conservation of function, albeit with a different client protein, as AIPL1 can function to modulate protein translocation and act as a putative chaperone. The major challenge now is to understand these functions in relation to retinal development and degeneration.
